YC Companies/Summer 2021/SFA Therapeutics
SFA Therapeutics logo

SFA Therapeutics

Regulating the immune system to block cancer & autoimmune diseases

Summer 2021Healthcare / Healthcare -> TherapeuticsPhiladelphia, PA, USA4 employees
AI-powered Drug Discovery
Anti-Aging
Biotech
Health & Wellness
Biotechnology

About

SFA Therapeutics is creating therapeutically-tailored oral drugs that regulate the immune system; with a focus on autoimmune diseases and cancers that originate from chronic inflammation. There are over 300 million patients who suffer from autoimmune diseases. Our treatment is designed to block the root cause of many of these chronic inflammatory diseases, with safe oral drugs. We have strong clinical data from a phase 1b clinical trial in psoriasis, and human data in pancreatic cancer, uveitis and NASH. we have a total of 9 drugs in our pipeline and 15 patents.

Build your own investing agent

GPAgent keeps YC listings public and neutral. Fund-specific scoring, notes, and workflow state live in each customer workspace.

Join the GPAgent waitlist

Founders (3)

Alla Arzumanyan
Founder
Ira Spector
Founder
Mark Feitelson
Founder

Details

Status
Active
Stage
Early
Team Size
4
Regions
United States of America, America / Canada, Remote, Partly Remote